This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit May 07, 2014


 

Advertisement

How safe is surgery for metastatic breast cancer?
Medscape (login required)
There are significantly more complications and deaths soon after primary surgery for metastatic breast cancer than for earlier-stage disease, according to a new retrospective study. Metastatic patients had a 30-day morbidity rate of 7.5 percent and a mortality rate of 1.8 percent, whereas the nonmetastatic group experienced corresponding rates of 3.7 percent and 0.1 percent. Metastatic disease was also an independent predictor of postoperative morbidity.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  


Shared decision-making improves patient satisfaction during radiation therapy
Oncology Nurse Advisor
Playing an active role in their radiation treatment decisions leaves patients with cancer feeling more satisfied with their care and may even relieve psychologic distress around the experience, researchers reported. In a study of 305 patients undergoing radiation treatment, Neha Vapiwala, MD, an associate professor in the department in radiation oncology at Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues found an association between patient satisfaction and patient-perceived control and shared decision-making.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Version 3 of the CP³R now available
ACS
The latest version of the Cancer Program Practice Profile Reports (CP³R) has been posted with the following features:
  • Data are displayed for diagnosis years 2009, 2010, and 2011.
  • Three new breast measures have been added (see more information at http://www.facs.org/cancer/qualitymeasures.html).
  • Registrars can edit codes that affect whether or not the case belongs in the denominator of the measures, replacing the function of the former "censor" button.
  • Navigation is simplified, and both facility and comparison performance rates update when changes are made.
  • Documentation is improved (see http://www.facs.org/cancer/ncdb/cp3r.html).

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


New chemotherapy combination improved OS in metastatic pancreatic cancer
HemOnc Today
The novel agent MM-398, combined with 5-FU and leucovorin, provided an OS of 6.1 months in patients with metastatic pancreatic cancer — a 1.9-month increase from the 4.2-month survival achieved with 5-FU plus leucovorin alone, according to a press release from Merrimack Pharmaceuticals, makers of MM-398. Patients included in the phase 3 NAPOLI-1 study were previously treated with a gemcitabine-based therapy across more than 100 sites in North America, South America, Europe, Asia, and Australia.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Register now for the 2014 CoC workshop — Strengthening Your Cancer Program...Enriching the Coordinators' Role
Commission on Cancer
On June 19-20 in Chicago, the Commission on Cancer (CoC) will hold a new workshop entitled Strengthening Your Cancer Program…Enriching the Coordinators' Role. This program provides information and case studies on the roles and responsibilities of the various CoC-designated coordinators. The two-day program will cover what the various coordinators' roles are, what their roles on the cancer committee involve, and how to meet and improve the required responsibilities based on the CoC Standards. Register for the program. Program fees are $650 if registration is received on or before May 15 and $750 if registration is received after May 15.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Vitamin D deficiency may predict aggressive prostate cancer
Medical News Today
According to study author Dr. Adam B. Murphy, assistant professor in the department of urology at the Northwestern University Feinburg School of Medicine in Chicago, Illinois, vitamin D is known to impact the growth and differentiation of benign and malignant prostate cells, both in prostate cell lines and animal models of prostate cancer. However, their study revealed that low levels of the vitamin in men appeared to predict the risk of aggressive prostate cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Study reveals how ovarian cancer metabolism changes between early, late stages
News Medical
A Rice University-led analysis of the metabolic profiles of hundreds of ovarian tumors has revealed a new test to determine whether ovarian cancer cells have the potential to metastasize, or spread to other parts of the body. The study also suggests how ovarian cancer treatments can be tailored based on the metabolic profile of a particular tumor. The research, which appears online in Molecular Systems Biology, was conducted at the Texas Medical Center in Houston by researchers from Rice, the University of Texas MD Anderson Cancer Center, and Baylor College of Medicine.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Register now — Strengthening Your Cancer Program...Utilizing the Rapid Quality Reporting System to Comply with the New Commendation Standard
Commission on Cancer
Strengthening Your Cancer Program...Utilizing the Rapid Quality Reporting System to Comply with the New Commendation Standard will be held on June 18 in Chicago, the day before the 2014 CoC Workshop. This workshop will provide important information to help your program comply with the new commendation standard that requires programs, from initial enrollment and throughout the three-year accreditation period, to participate in the Rapid Quality Reporting System (RQRS). Register now for the program; registration fees are $250 if registration is received on or before May 15 and $300 if registration is received after May 15, 2014.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Aggressive bladder cancer treatments underused
Renal & Urology News
Radical cystectomy and chemo-radiation are underused for muscle-invasive bladder cancer (MIBC) even though these treatments offer a survival benefit compared with other therapies or no treatment, new findings suggest. Using the National Cancer Data Base, Angela B. Smith, MD, of the University of North Carolina at Chapel Hill, and colleagues studied 36,469 patients with MIBC. Of these, 27 percent underwent radical cystectomy, 10 percent had chemo-radiation, 61 percent had other therapies, and 2 percent received no treatment.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Positive result for new DNA blood test for bowel cancer
Medical Xpress
A team of Australian scientists has presented evidence that a new blood test for bowel cancer based on two genes that "leak" into the blood can detect 65 percent of bowel cancer cases. The successful detection rate increased to 73 percent for cancers that are Stage II or higher. The data were presented in Chicago at the Digestive Diseases Week conference by Professor Graeme Young from the Flinders Centre for Innovation in Cancer at Flinders University.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


The Recovery Room Show — New episode available
ACS
You understand health, but do you understand medicine? Making sense of modern medicine, The Recovery Room, supported by the American College of Surgeons and hosted by Frederick L. Greene, MD, FACS, is an audio conversation with experts in surgery, medicine, ethics, and public health about the latest developments in medicine and health care. The latest episode, "Smoking Cessation and the Surgical Patient," is now available. It features Eric Skipper, MD, FACS, chief of adult cardiothoracic surgery at the Sanger Heart & Vascular Institute, Charlotte, N.C., and Michael Rosen, MD, FACS, professor of surgery and chief of GI and general surgery at Case Western Reserve University, Cleveland, Ohio.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Combined cetuximab and chemotherapy may speed colorectal cancer progression
Oncology Nurse Advisor
Cetuximab, used in combination with chemotherapy to treat advanced colorectal cancer,, is not effective in some settings and may even result in more rapid cancer progression. Because cetuximab is known to have activity in patients with CRC with the KRAS exon 2 wild-type, this population of patients was enrolled in the study. Researchers evaluated whether the drug cetuximab and chemotherapy together worked better than chemotherapy alone, in addition to a surgical procedure, for patients whose CRC had spread to the liver but could be surgically removed.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


National Accreditation Program for Breast Centers presents the Pursuing Excellence through Accreditation Workshop
NAPBC
Plan now to attend the Pursuing Excellence through Accreditation Workshop May 23 in Chicago. Designed for centers seeking accreditation for the first time as well as centers due for re-accreditation, this program will increase your understanding of the National Accreditation Program for Breast Centers (NAPBC) accreditation process and help you prepare for the survey visit. Space is limited, so please make sure you register early.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 
Advertisement

Advertisement



The CoC Brief

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Samantha Emerson, Content Editor, 469.420.2669
Contribute news

Disclaimer: The CoC Brief is a digest of the most important news selected for the American College of Surgeons Commission on Cancer from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Commission on Cancer does not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons and the Commission on Cancer.


Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of The CoC Brief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

April 30, 2014
April 23, 2014
April 16, 2014
April 16, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063